平阳霉素联合地塞米松治疗婴幼儿颜面部血管瘤的临床疗效观察

Treatment of orofacial hemangioma in infants with pinyangmycin intracavitary injection

目的：应用平阳霉素（PYM）与地塞米松（DXM）联合瘤腔内注射治疗婴幼儿颜面部血管瘤并观察其临床疗效。方法：54例婴幼儿颜面部血管瘤（61个瘤体）采用PYM、DXM联合行瘤腔内直接注射，1～2周重复，4～6次为一个疗程。结果：经6～24个月随访，治愈29例（53．70％），基本治愈20例（37．04％），有效5例（9．26％），治愈和基本治愈率90．74％。结论：PYM与DXM联合瘤腔内注射治疗婴幼儿颜面部血管瘤，具有疗程短、疗效好、副作用小、安全可靠等优点。

Objective：To evaluate the clinical effectiveness of combined Pinyangmycin and Dexamethasone intracavitary injection to treat orofacial hemangioma in infants. Method： Pinyangmycin and Dexamethasone were combined and injected into 61 cavities of the hernangioma in 54 infants, and such injection may be repeated every 1 -2 weeks. This process may contain 4-6 times. Result：All cases were followed up for 6-24 months. The cure and elementary cure rates were 90.74%, and there was no effectiveless case be found. Conclusion： The data suggested that the intracavitary injection of PYM combined DXM could be a safe, simple and effective therapy to orofacial hemandioma in infants.